TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03063320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice blend
Description: Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spice blend
Description: Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice blend
Description: Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
Study: NCT03137069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered orally, as per the dosing schedules described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered orally, as per the dosing schedules described above.
Study: NCT03060980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 20/60 mcg/day
Description: ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (oral)
Description: 10 mg/day and 25 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (oral)
Description: 1-6 mg/day
Study: NCT04202419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRAX 1940 nm laser
Description: A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
Study: NCT03792828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine HCl 30mg
Description: In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine HCl 30mg
Description: In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
Study: NCT01077921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
Study: NCT01541683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)
Description: Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)

Intervention type: OTHER
Group type: OTHER
Intervention: PEG solution (Fortrans®)
Description: 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
Study: NCT01760785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: divalproex sodium
Description: Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
Study: NCT00492635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
Study: NCT03771170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study: NCT02005861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow cells transplantation on collagen scaffold
Description: 120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant.
Study: NCT04009564

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Date coffee
Description: 45 g of date seeds coffee in 280 ml of water
Study: NCT04218851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole tablet
Description: POS tablet 300 mg taken orally
Study: NCT01918800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue: Take control
Description: Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MS: Take Control
Description: MS: Take Control includes topics of interest to people with MS other than fatigue.
Study: NCT00416481

Intervention type: BEHAVIORAL
Intervention: quality of life questionnaires
Study: NCT00119379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NucleomaxX
Description: NucleomaxX 36 grams TID every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
Study: NCT05372406

Intervention type: OTHER
Intervention: • no intervention
Description: • no intervention

Intervention type: OTHER
Intervention: • no intervention
Description: • no intervention
Study: NCT04009564

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal coffee
Description: 6 g of normal coffee in 280ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water, food colouring and coffee flavouring
Study: NCT01670305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Residual pockets will be treated by laser + photosensitizer
Description: Experimental group: Residual pockets will be treated by laser + photosensitizer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Residual pockets will be treated only photosensitizer
Description: Placebo Comparator: Residual pockets will be treated only photosensitizer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Residual pockets will be treated scaling and root planing
Description: Active Comparator: Residual pockets will be treated scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser + photosensitizer associated with scaling and root planing
Description: Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: furcation defects will be treated by scaling and root planing
Description: Active Comparator: furcation defects will be treated by scaling and root planing
Study: NCT01812668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib-s-malate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 d-FMAU
Description: Undergo 18F PET/FMAU PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 18F PET/FMAU PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04030156

Intervention type: PROCEDURE
Intervention: tonsillectomy
Description: Tonsillectomy was performed under general anesthesia using cold dissection method.

Intervention type: PROCEDURE
Intervention: tonsillectomy
Description: Tonsillectomy was performed under general anesthesia using cold dissection method.
Study: NCT01278940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells (DC) malignant melanoma
Description: The patients were assigned to intradermal or intranodal DC vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells (DC) malignant melanoma
Description: The patients were assigned to intradermal or intranodal DC vaccination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 were administrated by intranodal injection
Study: NCT00381290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
Study: NCT00847509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]FLT
Description: The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
Study: NCT03448484

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention (integrated package)
Description: Provided to all intervention households:~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* 8 birds of chicken (child consumes 1 egg/day)~* Vegetable seeds (red onion, indigenous managu and sukuma)~* Monthly trainings to all farmers on nutrition and WASH~* Micronutrient powder (MixMe, 1g sachet every third day)~* Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~* Agricultural training (every 2 weeks on average) for all~* Free to enrol for the following products on credit:~  * Compost boosters~ * Cook stoves~ * Seeds (onions, maize, indigenous greens, beans)~ * Maize storage bags~ * Drying tarps~ * Trees~ * Solar lights~ * Fertilizer~ * Actellic dust (insecticide)~ * Re-usable sanitary pads
Study: NCT03137264

Intervention type: DRUG
Intervention: Other
Description: Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
Study: NCT03227783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
Study: NCT04395261

Intervention type: DIAGNOSTIC_TEST
Intervention: Wideband Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Wideband Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Wideband Tympanometry
Study: NCT00482014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45
Study: NCT00939198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2 Skin Test Reagent
Description: Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
Study: NCT00913029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent
Description: iStent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost/timolol
Description: Combination latanoprost/timolol
Study: NCT03036293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten
Description: Tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten
Description: Tablet for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT01783678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study: NCT03227783

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
Study: NCT05189041

Intervention type: OTHER
Group type: OTHER
Intervention: Aneurysmal pulsation in functional MRI
Description: Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm

Intervention type: OTHER
Group type: OTHER
Intervention: Aneurysmal pulsation in functional MRI
Description: Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
Study: NCT01292824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
Study: NCT03921645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol antibiotics
Description: use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
Study: NCT00375609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Administered subcutaneously
Study: NCT03860818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health services delivery
Description: Technology-enabled pharmacist intervention
Study: NCT02249832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seated robot-assisted ankle therapy
Description: The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
Study: NCT02787629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous Intubation
Description: Intubation with GlideScope and ETT inserted simultaneously

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intubation
Description: Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
Study: NCT03919578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B vaccine
Description: Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B vaccine
Description: Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B vaccine
Description: Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B (Bio Farma)
Description: Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.